TIDMVERS

RNS Number : 2900U

Verseon Corporation

28 March 2019

March 28, 2019

Verseon Corporation

("Verseon" or the "Company")

Further Update to Admission of Subscription Shares

FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 22, 2019, the Directors now expect that Admission of the Subscription Shares, under a separate ISIN for Regulation S restricted stock, will take place on or around Tuesday, April 2, 2019.

About Verseon

Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find Verseon on Twitter and LinkedIn.

- Ends -

For further information, please contact:

 
 Verseon Corporation                        www.verseon.com 
 Sebastian Wykeham / Tina Schlafly          +1 (510) 225 9000 
 
 Arden Partners (NOMAD and Joint Broker) 
 Ruari McGirr / Ciaran Walsh / Alex          +44 (0) 20 7614 
  Penney                                      5900 
 
 Cantor Fitzgerald Europe (Joint Broker) 
                                            +44 (0) 20 7894 
 Phil Davies                                 7000

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd (PR Advisers) 
                                              +44 (0) 20 7466 
 Henry Harrison-Topham / Jamie Hooper          5000

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 821 
 Simon Vane Percy         890

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

FUREADDPAEANEEF

(END) Dow Jones Newswires

March 28, 2019 03:02 ET (07:02 GMT)

Verseon (LSE:VERS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Verseon Charts.
Verseon (LSE:VERS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Verseon Charts.